Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab-IRDye800CW fluorescence endoscopy in FAP
NL-OMON40163Withdrawn
- Sponsor
- University Medical Center Groningen
- Start
- Aug 2013
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of bevacizumab-IRDye800CW in Colonic Adenomatous Polyposis (3 arms), sponsored by University Medical Center Groningen. Primary endpoints: Sensitivity of bevacizumab-IRDye800CW for adenomatous polyp identification and Correlation of in vivo fluorescence with VEGF expression. Planned start Aug 2013; status: withdrawn.
02
Drugs
bevacizumab-IRDye800CW
03
Conditions
Colonic Adenomatous Polyposis
Beyond the preview
Go deeper on NL-OMON40163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40163.